AXSMA pretty solid start to the year
Axsome Therapeutics came out swinging in Q1 2026, posting $191.2 million in net product revenue — up 57% from a year ago. That’s the kind of growth that makes investors sit up a little straighter in their chairs.
The heavy lifting came from the usual suspects:
- AUVELITY generated $153.2 million in net product sales, up 59% year over year
- SUNOSI brought in $33.9 million, up 34%
- SYMBRAVO added $4.1 million
The pipeline keeps getting fatter
This wasn’t just a numbers dump. Axsome also said AUVELITY was approved for agitation associated with dementia due to Alzheimer’s disease, which is a meaningful expansion for a drug already doing the lion’s share of the revenue work.
The company also submitted an NDA to the FDA for AXS-12 in cataplexy linked to narcolepsy. And because apparently one pipeline milestone wasn’t enough, it added AXS-20 (balipodect), a pre-Phase 3 PDE10A inhibitor for schizophrenia and Tourette syndrome, to the lineup.
Why investors should care
Revenue growth is great, but biopharma investors usually want the triple combo: sales, approvals, and new shots on goal. Axsome is trying to deliver all three, and today’s update gives the bull case a little more juice.
The company said it’ll host a conference call today at 8:00 AM Eastern, so expect management to spend some time explaining how long this growth can last — the eternal biotech question, basically.
Big picture: Axsome isn’t acting like a one-drug story anymore, and that usually makes the market pay closer attention.